Loading...
| A00796 | Pages: 202 | Mar 2021 | 8907 Views | | |
| Author(s) : Trupti Wadekar, Sushant Terdale , Onkar Sumant | Tables: 100 | Charts: 41 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Plasma Fractionation Market
Request Now !The global plasma fractionation market was valued at $18,222 million in 2019, and is expected to reach $23,006 million by 2027, registering a CAGR of 6.2% from 2020 to 2027.
Fractionation is a process carried out to separate certain quantity of a mixture. Furthermore, plasma is the fluid component of blood, which is fractionated to obtain different plasma derivatives such as albumin and immunoglobulins. These derived plasma products have therapeutic effects and are employed in the treatment of various blood plasma related disorders. For instance, coagulation factor VIII is a plasma derivative, which is used for treatment and prophylaxis of hemophilia. Furthermore, it is also employed to stop excessive blood loss during surgical procedures. Similarly, immunoglobulins are employed in the treatment of primary and secondary immune deficiencies.
Get more information on this report : Request Sample Pages
Surge in geriatric population across the globe, which is predisposed to various rare diseases that require use of plasma derivatives is the major factor that boosts the plasma fractionation market growth.
Moreover, rise in use of immunoglobulins and alpha-1-antitrypsin in areas of medicine worldwide also fuels the growth of the plasma fractionation market. Furthermore, surge in plasma collection centers worldwide is another major factor that contributes toward the growth of the market. In addition, favorable government support to spread awareness related to use of plasma derived products also propels the growth of the plasma fractionation market. However, high cost of plasma derived products restricts growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period.
COVID-19 pandemic has affected every industry worldwide. For instance, after COVID-19 was declared as a pandemic by the WHO, countries worldwide adopted nationwide lockdowns to observe social distancing as a measure to contain the spread. This leads to disruption, limitation, challenges, and changes in each sector of every industry. Similarly, the plasma fractionation industry was also impacted by the pandemic. For instance, the outbreak of COVID-19 pandemic has led to decrease in number of blood donations and plasma collections, which hampers the market growth as it leads to shortage in raw material supply. However, decrease in raw material supply was compensated by fall in demand for plasma derivatives in the starting of nationwide lockdowns, as elective surgical procedures were postponed and availability of treatment for other medical conditions was also hampered. In addition, overall plasma supply in countries is maintained, however, some areas may face shortages. Thus, the viral outbreak had a negative impact on the plasma fractionation market.
The global plasma fractionation market is segmented on the basis of product, sector, and region. On the basis of product, the market is divided into albumin, immunoglobulins, coagulation factor VIII, and coagulation factor IX. By sector, the market is bifurcated into public sector and private sector. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Get more information on this report : Request Sample Pages
In terms of value, by product, immunoglobulin is the largest segment in the plasma fractionation market and is also expected to exhibit the fastest growth rate during the forecast period. The growth of this segment is attributable to diversified use of immunoglobulin in various disorders such as primary and secondary immune deficiencies, autoimmune diseases, and inflammatory diseases. Furthermore, surge in research related to immunology across the globe is another factor that contributes toward the growth of the immunoglobulin market.
In terms of value, by sector, the private sector acquired largest plasma fractionation market share during the forecast period. This is attributable to the fact that there are a large number of private players operating in the plasma fractionation industry, who collect and fractionate large amount of plasma into derivatives such as albumin and immunoglobulin. Thus, contribute toward plasma fractionation marker growth.
Get more information on this report : Request Sample Pages
Asia-Pacific presents lucrative opportunities for key players operating in the plasma fractionation market, owing to presence of governmental bodies that regulate and supervise plasma collection, fractionation, and sales is the major factor that boosts the market growth. In addition, surge incidences of medical conditions such as severe fever with thrombocytopenia syndrome (SFTS), hemophilia, and primary & secondary immune deficiencies also fuel the growth of the market. Furthermore, increase in geriatric population, rise in government support through Medicaid and healthcare policies, and developments in the healthcare infrastructure are other factors that drive the growth of the market. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive growth of the plasma fractionation market in the region.
The key players profiled in this report include Baxter International Inc., Bio product laboratory, Biotest AG, CSL Ltd., Grifols SA, Kedrion S.P.A (Kedrion Biopharma Inc.), LFB S. A., Octapharma AG, Sanquin Blood Supply Foundation, and Takeda Pharmaceutical Company Limited.
Get more information on this report : Request Sample Pages
Key Benefits For Stakeholders
Key Market Segments
By Product
By Sector
By Region
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.3.1.Bargaining power of buyers
3.3.2.Bargaining power of suppliers
3.3.3.Thereat of new entrants
3.3.4.Threat of substitutes
3.3.5.Intensity of competitive rivalry
3.4.Top player positioning, 2019
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Surge in geriatric population across, coupled with rise in prevalence of rare diseases
3.5.1.2.Rise in use of immunoglobulins in medicine
3.5.1.3.Increase in number of plasma collection centers across the globe
3.5.2.Restraint
3.5.2.1.High cost of plasma derived products
3.5.3.Opportunity
3.5.3.1.High growth potential in emerging economies
3.5.4.Impact Analysis
3.6.COVID-19 Impact analysis on plasma fractionation market
CHAPTER 4:PLASMA FRACTIONATION MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Albumin
4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Immunoglobulins
4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Coagulation factor VIII
4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast, by country
4.4.3.Market analysis, by country
4.5.Coagulation factor IX
4.5.1.Key market trends and growth opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:PLASMA FRACTIONATION MARKET, BY SECTOR
5.1.Overview
5.1.1.Market size and forecast
5.2.Public Sector
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Private Sector
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
CHAPTER 6:PLASMA FRACTIONATION MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by country
6.2.2.1.U.S.
6.2.2.1.1.U.S. plasma fractionation market, by product
6.2.2.1.2.U.S. plasma fractionation market, by sector
6.2.2.2.Canada
6.2.2.2.1.Canada plasma fractionation market, by product
6.2.2.2.2.Canada plasma fractionation market, by sector
6.2.3.North America market size and forecast, by product
6.2.4.North America market size and forecast, by sector
6.3.Europe
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by country
6.3.2.1.Germany
6.3.2.1.1.Germany plasma fractionation market, by product
6.3.2.1.2.Germany plasma fractionation market, by sector
6.3.2.2.UK
6.3.2.2.1.UK plasma fractionation market, by product
6.3.2.2.2.UK plasma fractionation market, by sector
6.3.2.3.France
6.3.2.3.1.France plasma fractionation market, by product
6.3.2.3.2.France plasma fractionation market, by sector
6.3.2.4.Turkey
6.3.2.4.1.Turkey plasma fractionation market, by product
6.3.2.4.2.Turkey plasma fractionation market, by sector
6.3.2.5.Russia
6.3.2.5.1.Russia plasma fractionation market, by product
6.3.2.5.2.Russia plasma fractionation market, by sector
6.3.2.6.Rest of Europe
6.3.2.6.1.Rest of Europe plasma fractionation market, by product
6.3.2.6.2.Rest of Europe plasma fractionation market, by sector
6.3.3.Europe market size and forecast, by product
6.3.4.Europe market size and forecast, by sector
6.4.Asia-Pacific
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by country
6.4.2.1.China
6.4.2.1.1.China plasma fractionation market, by product
6.4.2.1.2.China plasma fractionation market, by sector
6.4.2.2.Japan
6.4.2.2.1.Japan plasma fractionation market, by product
6.4.2.2.2.Japan plasma fractionation market, by sector
6.4.2.3.India
6.4.2.3.1.India plasma fractionation market, by product
6.4.2.3.2.India plasma fractionation market, by sector
6.4.2.4.South Korea
6.4.2.4.1.South Korea plasma fractionation market, by product
6.4.2.4.2.South Korea plasma fractionation market, by sector
6.4.2.5.Taiwan
6.4.2.5.1.Taiwan plasma fractionation market, by product
6.4.2.5.2.Taiwan plasma fractionation market, by sector
6.4.2.6.Indonesia
6.4.2.6.1.Indonesia plasma fractionation market, by product
6.4.2.6.2.Indonesia plasma fractionation market, by sector
6.4.2.7.Thailand
6.4.2.7.1.Thailand plasma fractionation market, by product
6.4.2.7.2.Thailand plasma fractionation market, by sector
6.4.2.8.Malaysia
6.4.2.8.1.Malaysia plasma fractionation market, by product
6.4.2.8.2.Malaysia plasma fractionation market, by sector
6.4.2.9.Vietnam
6.4.2.9.1.Vietnam plasma fractionation market, by product
6.4.2.9.2.Vietnam plasma fractionation market, by sector
6.4.2.10.Rest of Asia-Pacific
6.4.2.10.1.Rest of Asia-Pacific plasma fractionation market, by product
6.4.2.10.2.Rest of Asia-Pacific plasma fractionation market, by sector
6.4.3.Asia-Pacific market size and forecast, by product
6.4.4.Asia-Pacific market size and forecast, by sector
6.5.LAMEA
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by country
6.5.2.1.Brazil
6.5.2.1.1.Brazil plasma fractionation market, by product
6.5.2.1.2.Brazil plasma fractionation market, by sector
6.5.2.2.Kingdom of Saudi Arabia
6.5.2.2.1.Kingdom of Saudi Arabia plasma fractionation market, by product
6.5.2.2.2.Kingdom of Saudi Arabia plasma fractionation market, by sector
6.5.2.3.Rest of LAMEA
6.5.2.3.1.Rest of LAMEA plasma fractionation market, by product
6.5.2.3.2.Rest of LAMEA plasma fractionation market, by sector
6.5.3.LAMEA market size and forecast, by product
6.5.4.LAMEA market size and forecast, by sector
CHAPTER 7:COMPANY PROFILES
7.1.BAXTER INTERNATIONAL INC.
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.2.BIO PRODUCTS LABORATORY
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Key strategic moves and developments
7.3.BIOTEST AG
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments
7.4.CSL LTD.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.GRIFOLS SA
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.KEDRION S.P.A. (KEDRION BIOPHARMA INC.)
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.7.LFB S. A
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.8.OCTAPHARMA AG
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.SANQUIN BLOOD SUPPLY FOUNDATION
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments
7.10.TAKEDA PHARMACEUTICAL COMPANY LIMITED
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.PLASMA FRACTIONATION MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 02.PLASMA FRACTIONATION MARKET FOR ALBUMIN AND IMMUNOGLOBULIN, BY REGION, 2019–2027 (METRIC TONS)
TABLE 03.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII AND COAGULATION FACTOR IX, BY REGION, 2019–2027 (INTERNATIONAL UNITS (IU))
TABLE 04.PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION, 2019–2027 ($MILLION)
TABLE 05.PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY REGION, 2019–2027 (METRIC TONS)
TABLE 06.PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULIN, BY REGION, 2019–2027 ($MILLION)
TABLE 07.PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULIN, BY REGION, 2019–2027 (METRIC TONS)
TABLE 08.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY REGION, 2019–2027 ($MILLION)
TABLE 09.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY REGION, 2019–2027 (INTERNATIONAL UNITS (IU))
TABLE 10.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR IX, BY REGION, 2019–2027 ($MILLION)
TABLE 11.PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR IX, BY REGION, 2019–2027 (INTERNATIONAL UNITS (IU))
TABLE 12.PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 13.PLASMA FRACTIONATION MARKET FOR PUBLIC SECTOR, BY REGION, 2019–2027 ($MILLION)
TABLE 14.PLASMA FRACTIONATION MARKET FOR PRIVATE SECTOR, BY REGION, 2019–2027 ($MILLION)
TABLE 15.PLASMA FRACTIONATION MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 16.PLASMA FRACTIONATION MARKET, FOR ALBUMIN AND IMMUNOGLOBULIN, BY REGION, 2019–2027 (METRIC TONS)
TABLE 17.PLASMA FRACTIONATION MARKET, FOR COAGULATION FACTOR VIII & COAGULATION FACTOR IX, BY REGION, 2019–2027 (MILLION INTERNATIONAL UNITS)
TABLE 18.NORTH AMERICA PLASMA FRACTIONATION MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 19.U.S. PLASMA FRACTIONATION MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 20.U.S. PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 21.CANADA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 22.CANADA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 23.NORTH AMERICA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 24.NORTH AMERICA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 25.EUROPE PLASMA FRACTIONATION MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 26.GERMANY PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 27.GERMANY PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 28.UK PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 29.UK PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 30.FRANCE PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 31.FRANCE PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 32.TURKEY PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 33.TURKEY PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 34.RUSSIA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 35.RUSSIA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 36.REST OF EUROPE PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 37.REST OF EUROPE PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 38.EUROPE PLASMA FRACTIONATION MARKET, 2019–2027 ($MILLION)
TABLE 39.EUROPE PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 40.ASIA-PACIFIC PLASMA FRACTIONATION MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 41.CHINA PLASMA FRACTIONATION MARKET, 2019–2027 ($MILLION)
TABLE 42.CHINA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 43.JAPAN PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 44.JAPAN PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 45.INDIA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 46.INDIA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 47.SOUTH KOREA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 48.SOUTH KOREA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 49.TAIWAN PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 50.TAIWAN PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 51.INDONESIA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 52.INDONESIA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 53.THAILAND PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 54.THAILAND PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 55.MALAYSIA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 56.MALAYSIA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 57.VIETNAM PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 58.VIETNAM PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 59.REST OF ASIA-PACIFIC PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 60.REST OF ASIA-PACIFIC PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 61.ASIA-PACIFIC PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 62.ASIA-PACIFIC PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 63.LAMEA PLASMA FRACTIONATION MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 64.BRAZIL PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 65.BRAZIL PLASMA FRACTIONATION MARKET, BY PRODUCT BY SECTOR, 2019–2027 ($MILLION)
TABLE 66.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 67.KINGDOM OF SAUDI ARABIA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 68.REST OF LAMEA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 69.REST OF LAMEA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 70.LAMEA PLASMA FRACTIONATION MARKET, BY PRODUCT 2019–2027 ($MILLION)
TABLE 71.LAMEA PLASMA FRACTIONATION MARKET, BY SECTOR, 2019–2027 ($MILLION)
TABLE 72.BAXTER: COMPANY SNAPSHOT
TABLE 73.BAXTER: PRODUCT SEGMENT
TABLE 74.BAXTER: PRODUCT PORTFOLIO
TABLE 75.BIO PRODUCTS LABORATORY: COMPANY SNAPSHOT
TABLE 76.BIO PRODUCTS LABORATORY: OPERATING SEGMENTS
TABLE 77.BIO PRODUCTS LABORATORY: PRODUCT PORTFOLIO
TABLE 78.BIOTEST AG: COMPANY SNAPSHOT
TABLE 79.BIOTEST AG: OPERATING SEGMENTS
TABLE 80.BIOTEST AG: PRODUCT PORTFOLIO
TABLE 81.CSL LTD: COMPANY SNAPSHOT
TABLE 82.CSL LTD..: OPERATING SEGMENT
TABLE 83.CSL LTD..: PRODUCT PORTFOLIO
TABLE 84.GRIFOLS: COMPANY SNAPSHOT
TABLE 85.GRIFOLS: OPERATING SEGMENTS
TABLE 86.GRIFOLS SA: PRODUCT PORTFOLIO
TABLE 87.KEDRION: COMPANY SNAPSHOT
TABLE 88.KEDRION: OPERATING SEGMENTS
TABLE 89.KEDRION: PRODUCT PORTFOLIO
TABLE 90.LFB: COMPANY SNAPSHOT
TABLE 91.LFB: OPERATING SEGMENTS
TABLE 92.LFB: PRODUCT PORTFOLIO
TABLE 93.OCTAPHARMA: COMPANY SNAPSHOT
TABLE 94.OCTAPHARMA: OPERATING SEGMENTS
TABLE 95.OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 96.SANQUIN BLOOD SUPPLY FOUNDATION: COMPANY SNAPSHOT
TABLE 97.SANQUIN BLOOD SUPPLY FOUNDATION: OPERATING SEGMENTS
TABLE 98.SANQUIN BLOOD SUPPLY FOUNDATION: PRODUCT PORTFOLIO
TABLE 99.TAKEDA: COMPANY SNAPSHOT
TABLE 100.TAKEDA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.GLOBAL PLASMA FRACTIONATION MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MODERATE BARGAINING POWER OF BUYERS
FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05.HIGH THREAT OF NEW ENTRANTS
FIGURE 06.MODERATE THREAT OF SUBSTITUTES
FIGURE 07.MODERATE COMPETITIVE RIVALRY
FIGURE 08.TOP PLAYER POSITIONING, 2019
FIGURE 09.WORLD POPULATION AGED 65 AND OVER (%)
FIGURE 10.IMPACT ANALYSIS, PLASMA FRACTIONATION MARKET
FIGURE 11.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR ALBUMIN, BY COUNTRY, 2019 & 2027 (METRIC TONS)
FIGURE 13.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULIN, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR IMMUNOGLOBULIN, BY COUNTRY, 2019 & 2027 (METRIC TONS)
FIGURE 15.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY COUNTRY, 2019 & 2027 (INTERNATIONAL UNITS (IU))
FIGURE 17.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR IX, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR COAGULATION FACTOR VIII, BY COUNTRY, 2019 & 2027 (INTERNATIONAL UNITS (IU))
FIGURE 19.COMPARATIVE ANALYSIS OF PLASMA FRACTIONATION MARKET FOR PUBLIC SECTOR, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF PRIVATE SECTOR PLASMA FRACTIONATION MARKET FOR PRIVATE SECTOR, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 21.BAXTER: NET SALES, 2017–2019 ($MILLION)
FIGURE 22.BAXTER: REVENUE SHARE, BY SEGMENT 2019(%)
FIGURE 23.BAXTER: REVENUE SHARE, BY REGION 2019(%)
FIGURE 24.BIOTEST AG: NET SALES, 2017–2019 ($MILLION)
FIGURE 25.BIOTEST AG: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 26.BIOTEST AG: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 27.CSL LTD.: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.CSL LTD.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 29.CSL LTD.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 30.GRIFOLS: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.GRIFOLS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 32.GRIFOLS: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 33.KEDRION: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.KEDRION: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 35.OCTAPHARMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.SANQUIN BLOOD SUPPLY FOUNDATION: NET SALES, 2016–2018 ($MILLION)
FIGURE 37.SANQUIN BLOOD SUPPLY FOUNDATION: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 38.SANQUIN BLOOD SUPPLY FOUNDATION: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 39.TAKEDA: NET SALES, 2018–2020 ($MILLION)
FIGURE 40.TAKEDA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 41.TAKEDA: REVENUE SHARE, BY REGION, 2020 (%)
Plasma fractionation products are expected to witness high adoption in the future, owing to increase in number of plasma collection centers. In addition, the market exhibits high growth rate, owing to surge in awareness about use of plasma fractionation products in various medical aspects. Moreover, surge in geriatric population across the globe, which is predisposed to rare diseases that require plasma products for treatment also fuels growth of the market. North America and Asia-Pacific are expected to offer lucrative growth opportunities to key players. This is majorly attributed to factors such as improvement in healthcare facilities, rise in disposable income, and rapid improvement in economic conditions. However, high cost of plasma products hinders growth of the plasma fractionation market. Plasma fractionation product manufacturers and distributors have focused on expansion of their presence in emerging economies to strengthen their foothold in the market.
A. The total market value of plasma fractionation market is $18,222 million in 2019.
A. The forecast period for plasma fractionation market is 2020 to 2027
A. The market value of plasma fractionation market in 2019 is $15,073 million.
A. The base year is 2019 in plasma fractionation market
A. Top companies such as, CSL Limited, Grifols SA, Takeda Pharmaceutical Company Limited, Baxter International Inc. and Octapharma AG dominated the market in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
A. Albumin segment is the most influencing segment as it is used in various medical conditions such as acute liver failure, cardiopulmonary bypass and others. Furthermore, it is also used in liver failure.
A. The major factor that fuels the growth of the global plasma fractionation market includes surge in prevalence of rare diseases across the globe which leads to rise in demand for plasma fractionation products
A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as China with a CAGR of 6.7%. This is due to presence of governmental bodies that regulate and supervise plasma collection, fractionation, and sales is the major factor that boosts the market growth. In addition, surge incidences of medical conditions such as severe fever with thrombocytopenia syndrome (SFTS), hemophilia, and primary & secondary immune deficiencies also fuel the growth of the market.
A. Fractionation is a mechanical process carried out to separate a certain quantity of mixture. Plasma is the liquid part of blood which is yellowish and holds blood cells
A. Plasma derived products are known as plasma derivatives obtained from fractionation. These products are used in various medical fields such as in neurology, hematology, critical care, and immunology. For instance, in critical care, plasma is prescribed to prevent and stop bleeding
Enterprise
License/PDF
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
